Autoimmune Diseases  >>  Lemtrada (alemtuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lemtrada (alemtuzumab) / Sanofi
NCT00050778: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Checkmark AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
Checkmark
Oct 2013 - Oct 2013: 
Checkmark CAMMS223
More
Completed
2
334
US, Europe, RoW
Interferon beta-1a, Rebif®, Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
09/07
01/10
NCT01679041: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Terminated
2
1
US
Alemtuzumab, Fludarabine, Cyclophosphamide
Seah Lim M.D.
Multiple Sclerosis
11/13
11/13
CAM-THY, NCT01712945 / 2011-005606-30: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis

Terminated
1/2
40
Europe
Palifermin, Kepivance, keratinocyte growth factor, Alemtuzumab, Campath-1H
Cambridge University Hospitals NHS Foundation Trust
Multiple Sclerosis
08/17
10/17

Download Options